UARK 2003-35, A Phase III Study of Bortezomib Versus Bortezomib in Two Doses in Combination With Revlimid for Patients Relapsing or Progressing on Total Therapy II (UARK 98-026)
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2007
At a glance
- Drugs Lenalidomide (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Therapeutic Use
- 27 Dec 2007 Status changed from in progress to completed.
- 23 Aug 2007 The expected completion date for this trial is now 1 Jan 2015.
- 08 Sep 2005 New trial record.